SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors

This cohort study evaluates the association between sodium-glucose cotransporter 2 inhibitors and hyperkalemia in individuals with diabetes, heart failure, or chronic kidney disease receiving renin-angiotensin-aldosterone system inhibitors.

from JAMA Internal Medicine Online First https://ift.tt/RfObPxu